Huadao (Shanghai) Biomedical

Huadao Biomedical is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the development and industrialization of CAR-T cell therapies. The company is unique in its full-chain localization strategy, developing not only therapeutic candidates but also the proprietary automated manufacturing equipment, reagents, and consumables required for cell processing. This integrated approach aims to significantly reduce the high costs associated with CAR-T treatments, making them more accessible to patients. Its lead program, HD201, is a CD19-targeted CAR-T therapy currently undergoing clinical trials for B-cell malignancies. Huadao's technology platform, HD-CART, provides a closed and automated system for the efficient production of high-quality cell products.